----item----
version: 1
id: {DA991CC1-0A33-4303-A30C-91B56679D797}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/03/06/US quarterly results roundup
parent: {9649877C-55FC-4D13-B731-E8CE877A1D04}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: e0b72735-d0c1-431d-abf3-c1a58abdefec

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3429

<p><pre>Dianon Systems Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 Year 41.02 38.25 1.36 0.85 (ended Dec 31st)</pre><p>Dianon's revenues from anatomic pathology testing services rose 33% compared with the previous year, while molecular genetic testing services had even higher growth. Reimbursement pressures led to a decline in revenues from biomarker testing. Products in development at Dianon include the PSA II assay.</p><pre>Boston Scientific Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 121.61 101.09 23.18 20.31 Year 448.95 380.06 79.74 69.69 (ended Dec 31st)</pre><p>Boston Scientific spent about $7 million on R&D in the quarter, up 27% on the corresponding 1993 period, and $29.5 million (+23%) in the year. The company completed the acquisition of Scimed Life Systems on February 24th (see Clinica No 639, p 11).</p><pre>Tokos Medical Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 24.05 26.43 (2.43) (16.75) Year 100.70 120.84 (5.86) (26.38) (ended Dec 31st)</pre><p>Tokos specialises in maternal-neonate managed care services and obstetric home healthcare.</p><pre>Cabot Medical Revenues Net income ($ millions) ($ millions) 1995 1994 1995 1994 3 months 15.73 16.72 0.22 1.05 (ended Jan 28th, 1995; Jan 29th, 1994)</pre><p>Cabot manufactures and markets a range of devices for minimally invasive, gynaecological and urological surgical and diagnostic procedures.</p><pre>Diagnostic Products Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 37.91 26.77 5.01 3.02 Year 126.45 106.79 16.70 14.17 (ended Dec 31st)</pre><p>R&D spend by Diagnostic Products was $3.6 million in the fourth quarter, an increase of 15% over the 1993 quarter, and $13.4 million (+5%) in the year.</p><pre>Merit Medical Systems Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 3 months 8.88 7.10 (0.23) 0.54 Year 33.32 25.43 1.25 1.84 (ended Dec 31st)</pre><p>Merit's new manufacturing facility in Ireland, which is designed to provide 24-hour delivery in Europe, is expected to come on stream in June.</p><pre>Uromed Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months - - (1.99) (1.23) Year - - (7.61) (3.71) (ended Dec 31st)</pre><p>Uromed, which is preparing for commercialisation of its first product, the Reliance Urinary Control Insert, in Germany this year, had no revenues in 1994. At the end of last year, it filed a 510 (k) application for the Reliance Insert with the US FDA. The company ended 1994 with cash and equivalents of about $46 million.</p><pre>Bio-Vascular Revenues Net loss ($ millions) ($ millions) 1995 1994 1995 1994 3 months 2.13 1.57 (0.11) (0.24) (ended Jan 31st)</pre><p>Bio-Vascular's surgical revenues increased by 45% to $1.6 million in the quarter, boosted by demand for Peri-Strips, a staple reinforcement for lung surgery. Imaging revenues rose by 12% to about $525,000.</p><pre>Intelligent Surgical Lasers Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months - - (1.12) (1.66) 6 months - - (2.23) (3.03) (ended Dec 31st)</pre><p>ISL, which had no revenues in the first half of fiscal 1995, continues clinical trials with intrastromal photo-refractive keratectomy (ISPRK) in a number of indications, including Phase I trials for correction of short-sightedness. Cash and equivalents totalled almost $8 million at the end of last year.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{EBE9B072-7313-4B27-B849-CB50CD3B42E6}|{F5161CC2-772F-472E-A21C-BF196343462E}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950306T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950306T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950306T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT051755
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253524
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T183945Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

e0b72735-d0c1-431d-abf3-c1a58abdefec
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T183945Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
